Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Chugai Forms Strategic Investment Unit to Deepen Innovation Push; Record Japan Filings Eyed
Chugai Pharmaceutical has established a new Strategic Investment Department to beef up its M&A and investment activities, aiming to deepen collaborations with companies developing breakthrough technologies, President and CEO Osamu Okuda said on July 24. Speaking at an earnings briefing,…
To read the full story
Related Article
- Chugai CEO Says M&A an Option as Strategic Investment Unit Takes Shape
July 28, 2026
- Chugai Notches Strong H1 Growth on Key Products, Roche Exports
July 27, 2026
- Chugai to Launch US Partnering Office in January 2026
December 15, 2025
BUSINESS
- Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
October 2, 2026
- Novo Expands Oral Obesity Arsenal, Hengrui Asset Eyed around 2030
October 1, 2026
- Bayer Takes Dialogue-Driven Innovation Model Nationwide
October 1, 2026
- Chugai to Set Up South Korea Unit, Take Sales In-House
October 1, 2026
- Daito Reveals Meiji, DBJ as Partners in Kyorin Generics JV
October 1, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…